Navigation Links
Aethlon Medical Releases Shareholder Letter
Date:9/15/2009

SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc., (OTC Bulletin Board: AEMD) disclosed today that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders.

(Logo:http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)

    To our Shareholders:

    In advance of tomorrow's annual meeting, I wish to thank those
    shareholders who returned proxies supporting measures to re-elect our
    board of directors, reappoint our auditors, and increase the authorized
    shares of our common stock.  The results of your votes will be tabulated
    during our meeting and disclosed shortly thereafter.

    I would also like to take this opportunity to disclose that our
    manufacturing program with Bioserv/NextPharma Technologies is now
    underway, and that infectious disease researchers have provided initial
    verification that our Hemopurifier(R) is able to capture the emerging H1N1
    swine flu virus. We are additionally honored to reestablish a cooperative
    research and development agreement with the U.S. Army Medical Research
    Institute of Infectious Diseases (USAMRIID) that will continue our
    research into treating Ebola and other highly lethal pathogens.

    While I am pleased we have advanced these initiatives, our primary focus
    remains directed towards leveraging our therapeutic opportunity in
    Hepatitis-C care and establishing strategic relationships that will
    maximize long-term economic value for shareholders.  In this regard, we
    are actively pursuing relationships that offer to augment or
    significantly expand our clinical, distribution, and manufacturing
    capabilities.  However, I want to stress the complexity underlying any
    such relationship should not be underestimated.  We face issues that
    include competition between players in the medical device space, scaling
    of manufacturing at feasible costs, and developing appropriate
    distribution channels in a variety of markets.  Additionally, we maintain
    a firm stance that Aethlon Medical shareholders should maintain 100%
    ownership of our Hemopurifier(R) technology.  Regardless of these
    challenges, I am increasingly confident that we will establish
    relationships that provide us the foundation to transition our science
    into a successful business enterprise.

    On behalf of our dedicated team at Aethlon Medical, I thank you for your
    continued support and look forward to meeting those of you who attend
    tomorrow's meeting.

    Very truly yours,

    James A. Joyce
    Chairman, CEO

Certain of the statements within this shareholder letter may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the Company's ability to forge corporate partnerships on terms acceptable to the Company or at all, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

    Contacts:

    Jon Cunningham
    RedChip Companies Inc.
    (407) 644-4256
    (407) 491-4498 -cell
    Dave@redchip.com or Jon@redchip.com

    Jim Joyce
    Chairman, CEO
    858.459.7800 x301
    jj@aethlonmedical.com

    Jim Frakes
    Senior VP Finance
    858.459.7800 x300
    jfrakes@aethlonmedical.com


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Aethlon Medical to Present at Todays Southern California Investor Conference
2. Aethlon Medical Initiates Swine Flu Testing Program
3. Aethlon Medical Announces U.S. Army Agreement
4. Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
5. Aethlon Medical Discloses New HIV/AIDS Treatment Data
6. Aethlon Medical Confirms Hemopurifier(R) Is a Treatment Candidate Against Swine Flu Virus
7. Aethlon Medical Announces Engagement of RedChip Companies to Initiate Investor and Media Relations Programs
8. Aethlon Medical Announces CEO Interview and Corporate Presentation Available Online
9. Emergency Medical Transport By Air Carries Risks
10. Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress
11. Medical Doctor Creates Mantra Medicine Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... York, NY (PRWEB) , ... June 24, 2016 ... ... publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as a ... that “the most beautiful women in the world, and the most handsome men, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology: